Paclinab is a microtubule inhibitor indicated for the treatment of patients with Metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer, Metastatic adenocarcinoma of pancreas. It is recommended by guidelines such as NCCN and ESMO as first line regimens in metastatic pancreatic cancer in combination with gemcitabine and in nonsmall cell lung cancer in combination with carboplatin.
- Metastatic Breast Cancer: Paclinab is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Non-Small Cell Lung Cancer: Paclinab is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
- Adenocarcinoma of the Pancreas: Paclinab is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.